Results 61 to 70 of about 2,870,340 (221)
Anti‐platelet therapy: phosphodiesterase inhibitors [PDF]
British Journal of Clinical Pharmacology, 2011 Inhibition of platelet aggregation can be achieved either by the blockade of membrane receptors or by interaction with intracellular signalling pathways. Cyclic adenosine 3′,5′‐monophosphate (cAMP) and cyclic guanosine 3′,5′‐monophosphate (cGMP) are two critical intracellular second messengers provided with strong inhibitory activity on fundamental ...
GRESELE, Paolo +2 more
openaire +4 more sources
Phosphodiesterase type 5 inhibitors and erectile dysfunction
South African Family Practice, 2010 Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management
Catherine Whittaker
doaj +1 more source
PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS
International Journal of Clinical Practice, 2002 SUMMARYThe clinical properties (efficacy and safety profile) of a medicine are related not only to its mode of action, but also to its selectivity for its target (usually a receptor or enzyme) and are also influenced by its pharmacokinetic properties (absorption, distribution, metabolism and elimination).
J D, Corbin, S H, Francis
openaire +2 more sources
Dermatologic Therapy, 2017 The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult‐to‐treat disease. IL‐23 inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and Janus kinase (JAK) inhibitors are currently encouraging further ...
D. Wcisło-Dziadecka +4 more
semanticscholar +1 more source
Phosphodiesterase-5 inhibitors: Raynaud's and beyond
Indian Journal of Rheumatology, 2017 Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP).
Sanat Phatak +3 more
doaj
The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review
Journal of Cerebral Blood Flow and Metabolism, 2017 Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension.
M. Pauls +6 more
semanticscholar +1 more source
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
Global Cardiology Science & Practice, 2014 Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid ...
G. Butrous
semanticscholar +1 more source
Advances in the treatment of Raynaud’s phenomenon
Vascular Health and Risk Management, 2010 Terri L LevienDrug Information Pharmacist and Clinical Associate Professor, College of Pharmacy, Washington State University Spokane, WA, USAAbstract: Raynaud’s phenomenon is a common condition characterized by vasospasm of the digital arteries
Terri L Levien
doaj
Sexual function in hypertensive patients receiving treatment
Vascular Health and Risk Management, 2006 Thorsten Reffelmann, Robert A KlonerUniversity of Southern California, The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, Los Angeles, CA, USAAbstract: In many forms of erectile dysfunction (ED ...
Thorsten Reffelmann, Robert A Kloner
doaj
Ciprofloxacin-Induced Antibacterial Activity Is Attenuated by Phosphodiesterase Inhibitors
Current Therapeutic Research, 2015 Background: Ciprofloxacin is a commonly used antibiotic for urinary tract infection that interacts with bacterial topoisomerases leading to oxidative radicals generation and bacterial cell death.
Majed M. Masadeh, PhD +3 more
doaj +1 more source